After it was approved in 2019, Spravato, a depression treatment derived from the club drug ketamine, was looking like a dud. But recently it has taken off, and it surpassed $1 billion in annual sales last year for its maker, Johnson and Johnson.

Further Listening:

-A Lawyer Says He Doesn't Need Help for Psychosis. His Family Disagrees. 

-America's Maternal Mental Health Crisis 

Further Reading:

-J&J’s Ketamine-Derived Drug Is Taking Off 

-Big Pharma Walked Away From Mental Health. Why Some Are Coming Back. 

Learn more about your ad choices. Visit megaphone.fm/adchoices